Polymorphisms of the stem cell marker gene CD133 are associated the clinical outcome in a cohort of Chinese non-small cell lung cancer patients. Issue 8 (21st August 2017)

• Record Type: Journal Article
• Authors: Liu, Qing-Feng; Zhang, Zhi-Fei; Hou, Guang-Jie; Yang, Guang-Yu; He, Yi
• Is Part Of: BMJ open. Volume 7:Issue 8(2017)
• Publication Date: 2017-08-21
• Subjects: Non-small cell lung cancer -- CD133 polymorphism -- overall survival -- China; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-016913
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 ( rs2240688 A>C, rs10022537 T>A, rs7686732 C>G, and rs3130 C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients. Design: Retrospective cohort study. Setting: Department of General Surgery, in a general hospital, Henan Province, China. Participants: NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion. Those participants who were pregnant or breastfeeding, had a previous history of cancer, had other primary tumours, or who had had primary tumours of the skin and nasopharynx, were excluded from the study. Outcome measures: The primary endpoint was OS, which was calculated from the date of enrolment until the date of death or date of last follow-up. Results: There was a total of 1383 participants, with a median age of 63 years; 726 (52.5%) were male. Compared with the rs2240688 AA genotype, the variant AC/CC genotypes were independently associated with OS (HR 1.27, 95% CI 1.12 to 1.45 for AC genotype; HR 2.32, 95% CI 1.91 to 2.80 for CC genotype). Higher hazard ratios for associations between CD133 rs2240688 polymorphism and OS were observed in patients with adjuvant chemotherapy (HR 1.86, 95% CI 1.52 to 2.26) and radiotherapy for curative intent (HR 1.90, 95% CI 1.55 to 2.33). Conclusions: The study confirmed the significant association between the SNP rs2240688 A>C of CD133 and OS of NSCLC patients. Larger population-based studies in different ethnic groups are necessary to further validate the role and mechanisms of CD133 in NSCLC.